||
Medytox’s (086900.KQ) fat-reduction injectable “Neubeauju” has achieved more than half of its annual revenue target within two months of launch, showing rapid growth. The trend reflects rising demand to improve double chins and skin sagging after <a href="https://healthylife7.com/common-weight-loss-drugs-have-been-linked-to-a-higher-risk-of-hair-loss/" title="Common Weight Loss Drugs Have Been Linked to a Higher Risk of Hair Loss”>weight loss, as glucagon-like peptide (GLP)-1 obesity treatments have become widespread. As interest grows in body contouring beyond simple weight loss, the fat-reduction injectable market is entering a new growth phase
According to the industry on the 22nd, the number of medical institutions that have adopted Medytox’s fat-reduction injectable “Neubeauju” has expanded to about 300 nationwide. This comes roughly two months after its launch in late March. Cumulative sales also surpassed 10,000of this year’s annual revenue target, showing rapid growth
Neubeauju is a fat-reduction injectable indicated for improving moderate to severe submental fat in adult patients. It received product approval from the Ministry of Food and Drug Safety last September as the 40th domestically developed new drug
Neubeauju’s competitive edge lies in its differentiated ingredient. Most fat-reduction injectables currently available in Korea use deoxycholic acid (DCA) as their main ingredient. DCA, a type of bile acid, destroys fat cells through surfactant action, but its limitation has been noted as relatively frequent adverse reactions such as pain, swelling, and bruising
This differentiation, combined with recent changes in treatment trends, is seen as driving its popularity. While the fat-reduction effect itself was the key criterion for product selection in the past, an increasing number of medical practitioners now comprehensively consider ingredients, safety, and post-treatment recovery speed
This differentiation strategy is also translating into early sales performance. Some of Neubeauju’s pre-order volume was reflected in this year’s first-quarter results. Medytox posted first-quarter consolidated revenue of 60.7 billion won, operating profit of 7.4 billion won, and net profit of 7.9 billion won. Revenue fell 5% from a year earlier, but operating profit and net profit rose 35% and 136%, respectively, significantly improving profitability. The company plans to foster Neubeauju as a new growth engine to strengthen its aesthetics portfolio.
The market is also paying attention to Neubeauju’s growth potential. According to the brokerage consensus, Medytox’s annual revenue this year is projected at 265.2 billion won and operating profit at 33.4 billion won, up 7.2% and 96.4% from the previous year, respectively
The industry expects the fat-reduction injectable market to continue growing. The domestic market is estimated at about 30 billion won, and its size is expected to steadily expand as interest in body contouring rises alongside the spread of GLP-1 obesity treatments. As a result, market competition is expected to be reshaped away from simple price competition toward ingredient differentiation, clinical evidence, and ease of use for medical practitioners
“After the spread of GLP-1, there is a growing number of cases where patients who succeeded in weight loss also consider localized fat reduction and body contouring procedures to improve volume loss and skin sagging,” an industry official said. “This kind of change is acting as a key driver of growth in the fat-reduction injectable market.”
#Medytox#Neubeauju#Aesthetics#GLP1#BodyContouring#FatReduction#KoreaBiotech
Original reporting by Lee Jung-min for Seoul Economic Daily
AI-translated from Korean. Quotes from foreignxact original wording
View Korean originalTranslation Policy
Watch · Seoul Economic Daily
More →
Most Read This Week
1-5
- 1Which Country Will Buy KF-21 First? Indonesia, UAE, Philippines, Malaysia
- 2Airport Store Clerks Dismantle Shelf to Retrieve Japanese Tourist’s Earbuds, Win Award
- 3Airport Staff Injured as Chinese Tourists Cut Ahead in Incheon Queue
- 4Chip Turmoil Sends KOSPI on Roller Coaster, Fueled by Leverage ETFs
- 5Iran May Have Fired Maneuverable Missiles to Evade US Defenses
← Back to Home
